75% of autistic children stayed on CBD-rich cannabis treatment for 6 months with substantial reported benefits | Research

The takeaway

Among 87 autistic children receiving CBD-rich cannabis, 75% adhered to the 6-month treatment with relatively mild side effects and substantial parent-reported benefits, though some families struggled with dosing regimens and unrealistic expectations.

People interested in medical cannabis for autism and factors affecting treatment adherence in children.

75% adherence rate over 6 months

What the researchers found

75% adherence rate over 6 months. Side effects were relatively mild. Parents reported substantial benefits for children and families. Barriers included the complex intake regime, some side effects, and in certain cases unrealistic parental expectations about treatment outcomes.

Why it matters

Medical cannabis for autism is growing in use but adherence data are scarce. A 75% adherence rate is relatively high for a 6-month treatment in children, suggesting that when properly supported, families can maintain cannabis-based interventions for autism.

The numbers in context

87 autistic children. 75% adherence rate at 6 months. CBD-rich cannabis preparation. Relatively mild side effects. Barriers: intake regime, side effects, unrealistic expectations.

How the study worked

Explanatory sequential mixed-methods study of 87 autistic children and their families receiving 6-month CBD-rich cannabis treatment. Quantitative analysis of characteristics and adherence combined with qualitative parent interviews about benefits and barriers.

What this study cannot tell us

No control group or randomization. Parent-reported benefits may be biased by expectations. Single-center study. CBD-rich products vary, limiting generalizability to other formulations. 6-month timeframe may not reflect longer-term adherence.

How to read the evidence

Mixed-methods study with reasonable sample size. Limited by lack of control group, parent-reported outcomes, and single-center design.

When this study was published

Published in 2024 in Medical Cannabis and Cannabinoids.

The bigger picture

As more families explore cannabis for autism, understanding what supports treatment success becomes critical. This study identifies specific, addressable factors that can improve adherence, from simplifying dosing to setting realistic expectations.

Questions still open

Would longer follow-up show maintained or declining adherence? Which specific autism symptoms responded best to CBD-rich cannabis? How do adherence rates compare to conventional autism treatments?

Common questions

Do families stick with cannabis treatment for autism?

In this study, 75% of families maintained treatment over 6 months, which is relatively high. Those who dropped out often struggled with the dosing routine, side effects, or had expectations that did not match outcomes.

Were there significant side effects?

Side effects were described as relatively mild. The study noted that while some side effects contributed to dropout, the treatment was generally well-tolerated. The main barriers were practical (dosing regime) rather than safety-related.

Read the original research

Characteristics for Medical Cannabis Treatment Adherence among Autistic Children and Their Families: A Mixed-Methods Analysis.

Medical cannabis and cannabinoids, 7(1), 68-79

View on PubMed ↗Publisher’s paper ↗

Citation

David, Ayelet; Stolar, Orit; Berkovitch, Matitiahu; Kohn, Elkana; Waisman-Nitzan, Michal; Hartmann, Inbar; Gal, Eynat. (2024). Characteristics for Medical Cannabis Treatment Adherence among Autistic Children and Their Families: A Mixed-Methods Analysis.. Medical cannabis and cannabinoids, 7(1), 68-79. https://doi.org/10.1159/000538901